Cerebral hypoperfusion induces insulin resistance and exacerbates Alzheimer's Disease

This work examines how chronic cerebral hypoperfusion (CCH), modeled by bilateral carotid artery stenosis (BCAS) in male rats, produces sustained activation of the hypothalamic-pituitary-adrenal (HPA) axis and promotes systemic insulin resistance mechanisms that may exacerbate vascular contributions to cognitive impairment and dementia (VCID). Using 5-month-old male Sprague Dawley rats randomized to BCAS or sham surgery (n = 8 per group) and followed for 12 weeks, the investigators confirmed successful induction of CCH by measuring reductions in cerebral blood flow with laser speckle contrast imaging and assessed cognitive, endocrine, and metabolic outcomes. BCAS produced measurable reductions in cerebral blood flow and memory impairment, demonstrating the model's relevance to VCID.

Endocrine measures revealed elevated markers of HPA activation in BCAS rats compared with shams: plasma adrenocorticotropic hormone (ACTH) was significantly higher (117.2 ± 9.6 vs. 88.29 ± 9.1 pg/mL) and fecal corticosterone was increased (220 ± 21 vs. 146 ± 18 ng/g feces). Metabolic profiling showed a paradoxical pattern of hypoglycemia combined with hyperinsulinemia in BCAS animals: lower fasting blood glucose (68.1 ± 6.1 vs. 76.5 ± 5.9 mg/dL) accompanied by markedly increased fasting insulin (481.6 ± 242.6 vs. 97.94 ± 40.02 pmol/L). Homeostasis model assessment indices demonstrated insulin resistance in BCAS rats (HOMA-IR: 11.71 ± 6.47 vs. 2.62 ± 0.93). Glucose tolerance tests further indicated altered glucose handling, with BCAS rats showing lower blood glucose area under the curve than controls (250 ± 12 vs. 326 ± 20 mg/dL/h). Together, these findings support the hypothesis that chronic reductions in cerebral perfusion elicit sustained HPA axis activation leading to glucocorticoid excess and dysregulated insulin signaling.

The study frames CCH, glucocorticoid excess, and insulin resistance as participants in a potentially self-reinforcing cycle that can worsen cerebrovascular pathology and cognitive decline. Methodologically, the study adhered to institutional and NIH animal care guidelines and applied established BCAS techniques, perioperative analgesia and antibiotics, and serial physiological and behavioral assessments over a prolonged (12-week) period, enhancing the translational relevance of the findings to chronic vascular compromise in aging. By demonstrating that cerebrovascular insufficiency can itself drive systemic metabolic dysfunction, Lansdell et al. broaden the perspective on bidirectional interactions between vascular disease and metabolic risk factors in dementia pathogenesis.

The results imply that therapies targeting HPA dysregulation or insulin resistance might interrupt this deleterious cycle and potentially mitigate progression of VCID or vascular contributions to Alzheimer's disease. Future work could build on these results to determine causality, identify central versus peripheral mechanisms linking CCH to HPA activation, and test interventions to normalize glucocorticoid and insulin signaling in the context of chronic cerebral hypoperfusion.